News
-
-
PRESS RELEASE
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate -
-
-
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
HAEMATO AG, 100% subsidiary of M1 Kliniken AG, sells HAEMATO Pharm GmbH to PHOENIX group. Transaction details undisclosed. M1 Kliniken AG aims for global leadership in medical aesthetics